T-Cell Therapy: Options for Infectious Diseases

Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S217-24. doi: 10.1093/cid/civ615.


The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy.

Keywords: CAR; Mtb; T-cells; adoptive cell therapy; host-directed therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adoptive Transfer*
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Cytokines / therapeutic use
  • Extensively Drug-Resistant Tuberculosis / therapy
  • Humans
  • Immunity, Cellular
  • Mycobacterium tuberculosis / immunology
  • Receptors, Antigen, T-Cell / immunology
  • Recombinant Fusion Proteins
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation*
  • Tuberculosis, Multidrug-Resistant / therapy*


  • Cytokines
  • Receptors, Antigen, T-Cell
  • Recombinant Fusion Proteins